首页> 美国卫生研究院文献>SAGE Open Medical Case Reports >Resolution of new daily persistent headache by a tumor necrosisfactor alpha antagonist Venlafaxine
【2h】

Resolution of new daily persistent headache by a tumor necrosisfactor alpha antagonist Venlafaxine

机译:肿瘤坏死可缓解新的每日持续性头痛因子α拮抗剂文拉法辛

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

New daily persistent headache is a continuous, unremitting headache, notorious for its unresponsiveness to aggressive medical interventions. The underlying pathophysiology of new daily persistent headache is poorly understood resulting in unending, chronic pain. However, a prior study identified elevated tumor necrosis factor alpha within the cerebral spinal fluid of new daily persistent headache patients. Herein, we report on a patient who suffered with headache for 6 years failing to respond to over 20 different medical treatments, but found drastic improvement and eventual resolution with Venlafaxine. This drug binds to the 5-HT2A receptor inhibiting tumor necrosis factor alpha signaling. Therefore, we hypothesize a chronic inflammatory mechanism driving new daily persistent headache pathology.
机译:每天新出现的持续性头痛是连续的,持续的头痛,以其对积极的医学干预无反应而臭名昭著。人们对新的每日持续性头痛的潜在病理生理学知之甚少,导致无休止的慢性疼痛。但是,一项先前的研究发现,每天新出现的持续性头痛患者的脑脊髓液中肿瘤坏死因子α升高。在本文中,我们报道了一名头痛患者长达6年之久的患者,对20多种不同的治疗方法均无反应,但发现文拉法辛的治疗效果得到了显着改善并最终得到了解决。该药物与抑制肿瘤坏死因子α信号的5-HT2A受体结合。因此,我们假设一种慢性炎症机制驱动着新的每日持续性头痛病理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号